MedTrace Logo

Adjunctive Fosfomycin for Treatment of Staphylococcus Aureus Bacteraemia

NCT06695832 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 369

Last updated 2024-11-22

No results posted yet for this study

Summary

Staphylococcus aureus bacteraemia is a frequent and life-threatening infection, despite current standard antibiotic monotherapy. This study aims to clarify the role of fosfomycin as an adjunctive therapy for improving outcomes in patients with this serious infection. Two clinical trials suggested that adjunctive fosfomycin therapy might offer a clinical benefit in certain cases, but the results are inconclusive. We aim to analyse pooled data from these trials in order to identify subgroups of patients that might benefit most from this therapy.

Conditions

  • Staphylococcus Aureus Bacteremia

Sponsors & Collaborators

  • Institut d'Investigació Biomèdica de Bellvitge

    collaborator OTHER

  • Hospital Universitari de Bellvitge

    lead OTHER

Principal Investigators

  • Jordi Carratalà, Medical Doctor · Department of Infectious Diseases, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2025-01-31
Completion
2025-01-31

Countries

  • Australia
  • Canada
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06695832 on ClinicalTrials.gov